Skip to main content
SpringerLink
Log in

Alectinib/pralsetinib

Various toxicities and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Meng Y, et al. Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report. Annals of Translational Medicine 10: A67, No. 8, Apr 2022. Available from: URL: https://atm.amegroups.com/article/view/93470/html

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib/pralsetinib. Reactions Weekly 1910, 21 (2022). https://doi.org/10.1007/s40278-022-16856-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-16856-0

Search

Navigation